CSPC Innovation Pharmaceutical Co., Ltd.
300765
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 59.64 | -128.11% |
| 2025 | -212.18 | -130.64% |
| 2024 | 692.45 | 606.53% |
| 2023 | 98.01 | 628.41% |
| 2022 | 13.45 | -44.27% |
| 2021 | 24.14 | -7.71% |
| 2020 | 26.16 | 6.88% |
| 2019 | 24.47 | 3.42% |
| 2018 | 23.66 | -12.74% |
| 2017 | 27.12 | 6.12% |
| 2016 | 25.56 | -44.19% |
| 2015 | 45.79 | -29.86% |
| 2014 | 65.28 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 29.32 | -50.84% |
CH
|
|
| 20.24 | -66.06% |
FR
|
|
| 35.08 | -41.18% |
JP
|
|
| 1.57 | -97.37% |
BR
|
|
| -8.49 | -114.23% |
US
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.